A Phase I, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Efgartigimod (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; First in man
  • Sponsors argenx
  • Most Recent Events

    • 01 Mar 2018 Status changed from recruiting to completed.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Oct 2016 According to an arGEN-X media release, complete data set from the study will be presented at American Society of Hematology (ASH) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top